← All trials
NCT05378945
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- May 18, 2022
- Last posted
- Aug 18, 2022
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Oyster Point Pharma, Inc.Collaborator
- Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.